• Emerging Priorities in Liver Disease

    While the USA has seen increasing rates of acute hepatitis B and hepatitis C, as well as increasing cases of HIV linked to injecting drug use, other parts of the world such as Australia are on track to eliminate hepatitis C. 

  • Life Expectancy in the Modern ART Era

    This presentation summarised the latest data on life expectancy and the co-morbidities that are seen in people living with HIV and considered whether life expectancy has now ‘normalised’ in comparison with that of the HIV-negative population, drawing attention to the possible methodological biases and important subsets in whom life expectancy remains substantially shorter than desired.

  • Rapid Reduction in HIV Diagnoses after Targeted PrEP Implementation in NSW, Australia

    PrEP is effective in reducing recent HIV infections on a population state-wide level. More work is required to target harder-to-reach groups as PrEP was less effective in these groups in reducing recent HIV infections.

  • The Rapid ART Program Initiative for HIV Diagnosis (RAPID) in San Francisco

    Population-wide interventions/health-service design can reduce the time it takes from HIV diagnosis to first virologic suppression and the consequent population health benefits. In the RAPID program, 30% of patients commenced treatment within 5 days (2016) compared to 6% (2013). The time to virological suppression reduced from 134 days (2013) to 61 days (2016). Median days to virological suppression was 43-61 days in 2016.

  • Strategies for Improving the US Care Cascade: Confronting a Fragmented Health System

    There are many structural and other barriers which may prevent patients accessing care. Re-linking individuals to the same system of care that failed to engage them in the first place is not an effective strategy. For the hardest-to-reach patients, we need to change the structure of care available.


  • Switch to Bictegravir/F/TAF from DTG and ABC/3TC

    Bictegravir in a single-tablet regimen, which can be dosed without food, will become another treatment option available to HIV prescribers. It is safe and effective to switch patients from Dolutegravir/Abacavir/3TC.